dc.creator | Laskari K., Tektonidou P.M.G., Katsiari P.C., Athanassiou P., Dimopoulou D., Gerodimos C., Salamaliki C., Papagoras P.C., Settas P.L., Vassilopoulos P.D., Voulgari P.P.V., Zakalka M., Georgiadis A., Gkoni G., Daoussis P.D., Dimitroulas P.T., Iliou C., Kallitsakis I., Grika E.P., Mavragani P.C., Pikazis P.D., Raftakis J., Sarikoudis T., Kougkas N., Soukera D., Theodorou E., Tsatsani P., Tsiakou E., Vlachoyiannopoulos P.P., Vosvotekas G., Sfikakis P.P.P. | en |
dc.date.accessioned | 2023-01-31T08:48:58Z | |
dc.date.available | 2023-01-31T08:48:58Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1016/j.semarthrit.2020.10.011 | |
dc.identifier.issn | 00490172 | |
dc.identifier.uri | http://hdl.handle.net/11615/75698 | |
dc.description.abstract | Objective: To assess the efficacy and safety of the IL-1b inhibitor canakinumab in all adults with refractory Still's disease identified from the National Organization For Medicines for off-label drug use. Methods | en |
dc.language.iso | en | en |
dc.source | Seminars in Arthritis and Rheumatism | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098193236&doi=10.1016%2fj.semarthrit.2020.10.011&partnerID=40&md5=298475a7497abe2343fbb7c76350140c | |
dc.subject | abatacept | en |
dc.subject | anakinra | en |
dc.subject | canakinumab | en |
dc.subject | corticosteroid | en |
dc.subject | immunoglobulin | en |
dc.subject | methotrexate | en |
dc.subject | methylprednisolone | en |
dc.subject | tocilizumab | en |
dc.subject | tumor necrosis factor inhibitor | en |
dc.subject | antirheumatic agent | en |
dc.subject | biological product | en |
dc.subject | canakinumab | en |
dc.subject | monoclonal antibody | en |
dc.subject | adolescent | en |
dc.subject | adult | en |
dc.subject | adult onset Still disease | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | clinical article | en |
dc.subject | cohort analysis | en |
dc.subject | disease activity | en |
dc.subject | disease resistance | en |
dc.subject | drug dose intensification | en |
dc.subject | drug efficacy | en |
dc.subject | drug megadose | en |
dc.subject | drug safety | en |
dc.subject | drug withdrawal | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | genital tract infection | en |
dc.subject | human | en |
dc.subject | leukopenia | en |
dc.subject | longitudinal study | en |
dc.subject | macrophage activation syndrome | en |
dc.subject | male | en |
dc.subject | monotherapy | en |
dc.subject | mouth infection | en |
dc.subject | multicenter study | en |
dc.subject | onset age | en |
dc.subject | pneumonia | en |
dc.subject | priority journal | en |
dc.subject | relapse | en |
dc.subject | remission | en |
dc.subject | respiratory tract infection | en |
dc.subject | retrospective study | en |
dc.subject | skin infection | en |
dc.subject | soft tissue infection | en |
dc.subject | treatment outcome | en |
dc.subject | treatment response | en |
dc.subject | urinary tract infection | en |
dc.subject | clinical trial | en |
dc.subject | off label drug use | en |
dc.subject | treatment outcome | en |
dc.subject | Adult | en |
dc.subject | Antibodies, Monoclonal, Humanized | en |
dc.subject | Antirheumatic Agents | en |
dc.subject | Biological Products | en |
dc.subject | Humans | en |
dc.subject | Off-Label Use | en |
dc.subject | Retrospective Studies | en |
dc.subject | Still's Disease, Adult-Onset | en |
dc.subject | Treatment Outcome | en |
dc.subject | W.B. Saunders | en |
dc.title | Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients | en |
dc.type | journalArticle | en |